Limes Schlosskliniken AG (LIK:XETRA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Limes Schlosskliniken AG stock forecast from 0 analysts, the average analyst target price for Limes Schlosskliniken AG is not available over the next 12 months. Limes Schlosskliniken AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Limes Schlosskliniken AG is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Limes Schlosskliniken AG’s stock price was EUR 358.00. Limes Schlosskliniken AG’s stock price has changed by +4.07% over the past week, +18.54% over the past month and +8.48% over the last year.
No recent analyst target price found for Limes Schlosskliniken AG
No recent average analyst rating found for Limes Schlosskliniken AG
Company Overview Limes Schlosskliniken AG
LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services in Germany and Switzerland. It focuses on the treatment of stress-related illnesses and mental and emotional disorders, such as depression, acute burnout, affective disorders, trauma/PTSD, anxiety disorders, attention deficit hyperactivity disorder, psychosis, chronic pain, obsessive compulsive disorder, sleep disorder, somatoform disorder, and personality disorder. It also operates a sports psychiatry. The company was formerly known as GMF Capital AG and changed its name to LIMES Schlosskliniken AG in December 2005. LIMES Schlosskliniken AG was founded in 2005 and is headquartered in Cologne, Germany. Address: Kaiser-Wilhelm-Ring 26, Cologne, Germany, 50672 Read Less
LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services in Germany and Switzerland. It focuses on the treatment of stress-related illnesses and mental and emotional disorders, such as depression, acute burnout, affective diso...Read More
Frequently Asked Questions About Limes Schlosskliniken AG (LIK:XETRA) Stock
Stock Target Advisor's fundamental analysis for Limes Schlosskliniken AG's stock is Slightly Bullish .
Unfortunately we do not have enough data on LIK:XETRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on LIK:XETRA's stock to indicate what its average analyst target is.
LIK:XETRA stock's Price/Earning ratio is 31.70.
Our analysis grades LIK:XETRA stock's Price / Earning ratio at F. This means that LIK:XETRA stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Medical Care Facilities sector in the XETRA exchange.
Based on this LIK:XETRA may be fairly valued for its sector
The last closing price of LIK:XETRA's stock was EUR 358.00.
The most recent market capitalization for LIK:XETRA is EUR 0.10B.
Unfortunately we do not have enough analyst data on LIK:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Limes Schlosskliniken AG's stock.
As per our most recent records Limes Schlosskliniken AG has 177 Employees.
Limes Schlosskliniken AG's registered address is Kaiser-Wilhelm-Ring 26, Cologne, Germany, 50672.
You can get more information about it from Limes Schlosskliniken AG's website at https://www.limes-schlosskliniken.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LIK:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
